Keyphrases
Programmed Death-ligand 1 (PD-L1)
100%
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Cas9 Protein
100%
Antitumor Efficacy
100%
Tumor Cells
40%
Cell Therapy
20%
Therapeutic Efficacy
20%
Cancer Treatment
20%
Clinical Potential
20%
Gene Editing
20%
Checkpoint Inhibitors
20%
T-cell Mediated
20%
Chimeric Antigen Receptor T-cell Therapy
20%
Hypo
20%
Tumor Xenograft
20%
Anti-CD19 chimeric Antigen Receptor T Cells
20%
4-1BB
20%
Tumor Clearance
20%
Xenograft Model
20%
Anti-CD19
20%
Programmed Death-ligand 1 Expression
20%
Subcutaneous Xenograft
20%
Lentiviral Transduction
20%
Inhibitory Checkpoints
20%
T Cell Inhibitors
20%
Cas9 Ribonucleoprotein
20%
Anti-tumor Response
20%
Precision Genome Engineering
20%
Medicine and Dentistry
Neoplasm
100%
Chimeric Antigen Receptor T-Cell
100%
Clustered Regularly Interspaced Short Palindromic Repeat
100%
Cas9
100%
Tumor Cell
33%
Programmed Death 1 Ligand 1
33%
Combination Therapy
16%
In Vitro
16%
Cell Therapy
16%
Cancer Therapy
16%
Programmed Death 1 Receptor
16%
Tumor Xenograft
16%
Ribonucleoprotein
16%
Xenograft
16%
Genome Engineering
16%
Chimeric Antigen Receptor T-Cell Immunotherapy
16%
Immunotherapy
16%
Biochemistry, Genetics and Molecular Biology
CRISPR/Cas9
100%
Chimeric Antigen Receptor
100%
T Cell
100%
Genome Editing
28%
Cas9
28%
CD19
28%
Cell Death
14%
Synapsin I
14%
Ribonucleoprotein
14%
Immunology and Microbiology
CRISPR/Cas9
100%
Chimeric Antigen Receptor T-Cell
100%
Xenograft
33%
Tumor Cell
33%
CD19
33%
Programmed Death 1 Ligand 1
33%
Chimeric Antigen Receptor T-Cell Therapy
16%
Genome Editing
16%
Gene Editing
16%
Programmed Death 1 Receptor
16%
Immunotherapy
16%